Estrella Immunopharma Inc. (ESLA NASDAQ) stock market data APIs
$1.1371
0.01(0.9%)
as of June 5, 2026
Try our APIs with
free plan!
Estrella Immunopharma Inc. Financial Data Overview
Price chart is built with
Anychart
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Prev. Close
1.1371
Open
1.1423
High
1.1427
Low
1.0929
52 wk Range
0.78-3.15
Market Cap
49 059 K
Shares Outstanding
43 034 K
EPS
-0.01
Beta
0.854
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Estrella Immunopharma Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Estrella Immunopharma Inc. data using free add-ons & libraries
Get Estrella Immunopharma Inc. Fundamental Data
Estrella Immunopharma Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Estrella Immunopharma Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-18
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Estrella Immunopharma Inc. News
New
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
EMERYVILLE, Calif., March 23, 2026--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD2...
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Initiating Coverage We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with a valuation of $12.00 per share and ...
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?
One thing I like about Barchart’s Top 100 Stocks to Buy list is that it reminds me that stocks are expensive relative to historical norms. However, there’s still a lot of optimism that stocks wil...
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up
* Estrella Immunopharma (NASDAQ:ESLA [https://seekingalpha.com/symbol/ESLA]) entered into a securities purchase agreement for a private investment in public equity financing, expected to raise ~$3.3...
Get Estrella Immunopharma Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
